São Paulo Oncologist to be Honored for Lifetime Scientific Achievement

São Paulo Oncologist to be Honored for Lifetime Scientific Achievement

Press Release
Sep 11, 2018

The International Association for the Study of Lung Cancer to Present Joseph W. Cullen Prevention/Early Detection Award to Nise Yamaguchi

DENVER - Prominent São Paulo oncologist and immunologist,Nise Yamaguchi, M.D., Ph.D., will be recognized by the International Association for the Study of Lung Cancer (IASLC) with a Distinguished Award at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada. Dr. Yamaguchi will accept the Joseph W. Cullen Prevention/Early Detection Award, honoring her lifetime scientific achievements in research on the prevention of thoracic malignancies.

Dr. Yamaguchi is the clinical director of Instituto Avanços de Medicina in São Paulo, Brazil, where she has treated more than 12,000 patients since her start in the role in 1994. She is also senior scientist at the International Prevention Research Institute and co-founder of the World Cancer Alliance in Lyon, France, where she collaborates to expand access to cancer treatment in low- and middle-income countries.

“For many years, Dr. Nise Yamaguchi has been pioneering and advocating for tobacco control policies in Latin America and particularly in Brazil,” said Fred R. Hirsch, M.D., Ph.D., CEO of the IASLC. “Because the IASLC is an international organization with global responsibilities, we are proud to acknowledge and honor Dr. Yamaguchi’s important work in Latin America and in promoting the IASLC’s mission in this region.”

Dr. Yamaguchi was instrumental in establishing the IASLC Latin America Conference on Lung Cancer (LACLC), which brings younger and more established investigators from the region together to facilitate collaborative research and education on lung cancer prevention, early detection and treatment in Latin America.

Over the last 20 years, Dr. Yamaguchi has also been an active participant in serval clinical studies on lung and other cancers at the University of São Paulo. Her current research interests include personalized medicine in cancer and tumor immunology. In 2004, she founded and continues to coordinate the biannually-held Latin American Forum on Tobacco Control, focused on encouraging regional public policy implementation for the prevention of lung cancer. She has also authored or co-authored several publications and professional articles.

Dr. Yamaguchi is a graduate of the Faculty of Medicine of the University of São Paulo with a master’s in tumor immunology and a doctorate in pulmonology. During her studies, she participated in scientific immersions with cancer researchers at the MD Anderson Cancer Center in Houston on the aspects of tumor immunology, on which her master’s thesis in the discipline of immunology is based.

Dr. Yamaguchi will be honored on September 23, 2018 at the Opening Plenary Session at the IASLC 19th WCLC in Toronto, Canada. The IASLC WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The IASLC 19th WCLC will take place in Toronto on September 23-26, 2018. The Distinguished Awards are presented each year at the WCLC to the IASLC scientists who have demonstrated excellence in the field of lung cancer research and prevention.

About the WCLC:

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit www.iaslc.org. Follow the conference on social media with: #WCLC2018.

About the IASLC:

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on TwitterFacebookLinkedIn and Instagram.

Share